相关实验视频

Updated: Jun 24, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

在先天性心脏病的混合干预

Arash Salavitabar¹, Aimee K Armstrong¹, Sergio A Carrillo¹

¹The Heart Center, Nationwide Children's Hospital, The Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USA.

Interventional cardiology clinics

|June 5, 2024

概括

混合干预结合了干预性心脏病学和心胸外科手术来治疗先天性心脏病 (CHD). 这些综合方法克服了单一技术的局限性,改善了复杂心脏病的治疗选择.

科学领域:

心脏病学心脏病学
心胸外科手术心胸外科手术
干预心脏病学干预心脏病学

背景情况:

先天性心脏病 (CHD) 带来了复杂的解剖学和生理学挑战.
传统的外科手术和皮肤穿方法在治疗某些心血管疾病病例方面存在局限性.
混合干预整合了干预性心脏病学和心胸外科手术,以解决这些局限性.

研究的目的:

对先天性心脏病的关键混合干预方法进行审查和描述.
要突出混合程序在CHD管理中的协作性质.
为了说明混合技术如何克服独立方法的局限性.

主要方法:

审查现有的关于CHD混合干预的文献.
对常见和复杂的CHD病变的各种混合策略的描述.
讨论混合方法的优势和适用性.

主要成果:

混合干预为患者体型,血管通道或疾病严重程度所限制的病例提供解决方案.
这些综合方法可以规避纯粹手术或穿皮技术固有的局限性.
在CHD干预中,已经成功应用了几种重要的混合策略.

结论:

混合干预措施在治疗先天性心脏病方面取得了重大进展.
干预性心脏病学和心胸外科手术之间的合作对于成功的混合方法至关重要.
这些综合方法扩大了复杂心脏病的治疗可能性,改善了患者的治疗结果.

关键词:

大动脉支架植入植入植入耳前隔膜缺陷创建创建的缺陷遗传性心脏病是一种先天性心脏病.出生干预心脏病学的先天性干预心脏病学混合干预措施是混合干预措施.缺血性左心综合征是什么意思跨导管植入装置的植入方式室腔隔膜缺陷闭合闭合

更多相关视频

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training

Published on: February 10, 2022

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...